Erica Herzog, MD, PhD

Erica Herzog, MD, PhD
Associate Professor of Medicine
Director, Yale-ILD, the Center of Excellence for Interstitial Lung Disease at Yale
Director, Translational Lung Research Program
Co-Director, Yale Fibrosis Program
Assistant Director, Medical Student Research
Yale School of Medicine

Play

CME/CE Information

Activity Title Comorbidities and Complications of IPF
Topic Idiopathic Pulmonary Fibrosis
Accreditation Type AMA PRA Category 1 Credits™
Release Date December 31, 2014
Expiration Date December 30, 2015
Estimated Time to Complete Activity 30 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Identify approaches to IPF management that are covered in current guidelines, taking into account the strength of relevant recommendations
  • Formulate a plan, based on available data and expert consensus, for addressing acute exacerbations of IPF
  • Explain the impact and treatment of common comorbidities of IPF

ACTIVITY FACULTY

Erica Herzog, MD, PhD
Associate Professor of Medicine
Director, Yale-ILD, the Center of Excellence for Interstitial Lung Disease at Yale
Director, Translational Lung Research Program
Co-Director, Yale Fibrosis Program
Assistant Director, Medical Student Research
Yale School of Medicine

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice, the perception of commercial bias, and whether or not the objectives were met.
  6. Your CME/CE certificate will be available for download.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS


SPONSOR

This activity is sponsored by The France Foundation.


TARGET AUDIENCE

This activity is intended for physicians, surgeons, critical care clinicians, advanced practice nurses, and other health care professionals involved in the diagnosis and management of patients with IPF.

STATEMENT OF NEED

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis. Today, median survival time from diagnosis of IPF is two to five years. In 2011 an international committee of the American Thoracic Society (ATS) and European Respiratory Society (ERS) published updated guidelines for the diagnosis and management of patients with IPF. These are still challenges for health care providers who treat patients with IPF. These include acute exacerbations and comorbid conditions commonly seen in patients with IPF. In October 2014 the FDA approved two new drugs for the treatment of IPF. These therapies transform the management of IPF and present new options for practitioners and patients.

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Steering Committee Disclosures–Content Creators

The following faculty has indicated he/she has relationships with industry to disclose relevant to the content of this CME activity:

  • Steven Nathan, MD, has received grants/research support from Actelion, Boehringer Ingelheim, InterMune, United Therapeutics, and Veracyte. He has served as a consultant for Actelion, Bayer Pharmaceuticals, Boehringer Ingelheim, Gilead Sciences, InterMune, Roche, and United Therapeutics. He has also received honoraria from Actelion, Gilead Sciences, and United Therapeutics.
  • Harold Collard, MD, has received grants/research support from Boehringer Ingelheim, Genentech, UCSF and the National Heart, Lung, and Blood Institute (NHLBI). He has served as a consultant for Bayer, Biogen Idec, FibroGen, Gilead, InterMune, Mesoblast, Moerae Matrix, Pfizer, Promedior, and Takeda.
  • Kevin Flaherty, MD, has received grants/research support from InterMune, Boehringer Ingelheim, Bristol-Myers Squibb and NIH. He has served as a consultant for InterMune, Boehringer Ingelheim, Veracyte and Roche. He has also served on the Gilead Data and Safety Management Board.
  • Jonathan Goldin, MD, has received grants/research support from the NIH SLS II study and has served as a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, and Genentech. He also is a stock shareholder of MedQIA.
  • David Lederer, MD, has served as a consultant for Gilead, Immuneworks, InterMune.
  • Kevin Leslie, MD, has a contract to review slides for clinical trial diagnosis validation for Parexel, Inc. He also has received book royalties from Elsevier Sciences, Inc.
  • Paul Noble, MD, has served as a consultant for Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, InterMune, Moerae Matrix, Roche, and Takeda.
  • Amy Olson, MD, has served as a consultant on the advisory board for Boehringer Ingelheim.
  • Glenn Rosen, MD, has served as a consultant for Boehringer Ingelheim, Gilead, InterMune, and Takeda Pharmaceuticals.
  • Luca Richeldi, MD, PhD has received grants/research support from Boehringer Ingelheim and InterMune, and has served as a consultant for Biogen Idec, Boehringer Ingelheim, ImmuneWorks, InterMune, MedImmune, Roche, Sanofi-Aventis, and Takeda. He has received honoraria from Shionogi.
  • Jeffrey J. Swigris, DO, MS, has served as a consultant for Genentech and Boehringer Ingelheim.

The following faculty has indicated he/she has no relationships with industry to disclose relative to the content of this CME activity:

  • Anne Whitney Brown, MD

Faculty Disclosures–Activity Faculty

The following faculty has indicated she has relationships with industry to disclose relative to the content of this CME activity:

  • Erica Herzog, MD, PhD has received grants/research support from Boehringer Ingelheim, Biogen Idec, Galera, Promedior, and Sanofi. She has served as a consultant for Boehringer Ingelheim.

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Intermune.

DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Bayer Global assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2014 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..

Play



Access other Therapeutic Areas: